180 related articles for article (PubMed ID: 19443405)
1. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
[TBL] [Abstract][Full Text] [Related]
2. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A
J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019
[TBL] [Abstract][Full Text] [Related]
4. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
5. First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer.
Papanikolaou G; Fotopoulou C; Braicu I; Chekerov R; Schmidt SC; Pietzner K; Sehouli J
Anticancer Res; 2011 Aug; 31(8):2603-8. PubMed ID: 21778311
[TBL] [Abstract][Full Text] [Related]
6. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
[TBL] [Abstract][Full Text] [Related]
7. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
[TBL] [Abstract][Full Text] [Related]
8. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
9. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
Riechelmann H; Wiesneth M; Schauwecker P; Reinhardt P; Gronau S; Schmitt A; Schroen C; Atz J; Schmitt M
Cancer Immunol Immunother; 2007 Sep; 56(9):1397-406. PubMed ID: 17273869
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
11. Detection of disseminated tumor cells in patients with gynecological cancers.
Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
[TBL] [Abstract][Full Text] [Related]
12. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Shen J; Zhu Z
Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
[TBL] [Abstract][Full Text] [Related]
13. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
14. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
[TBL] [Abstract][Full Text] [Related]
15. Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma.
Buchner A; Riesenberg R; Kotter I; Hofstetter A; Stief C; Oberneder R
Cancer; 2006 Apr; 106(7):1514-20. PubMed ID: 16518813
[TBL] [Abstract][Full Text] [Related]
16. Rating of isolated disseminated tumor cells in bone marrow in comparison with other factors of prognosis in breast carcinoma.
Leinung S; Würl P; Schönfelder A; Weiss CL; Röder I; Schönfelder M
Int J Surg Investig; 2000; 2(3):193-202. PubMed ID: 12678519
[TBL] [Abstract][Full Text] [Related]
17. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.
Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G
Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970
[TBL] [Abstract][Full Text] [Related]
18. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method.
Naume B; Borgen E; Tøssvik S; Pavlak N; Oates D; Nesland JM
Cytotherapy; 2004; 6(3):244-52. PubMed ID: 15203981
[TBL] [Abstract][Full Text] [Related]
19. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
20. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients.
Woelfle U; Breit E; Zafrakas K; Otte M; Schubert F; Müller V; Izbicki JR; Löning T; Pantel K
J Immunol Methods; 2005 May; 300(1-2):136-45. PubMed ID: 15907331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
